title: The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).
abstract: BACKGROUND
  Complete lymph node dissection, the current standard treatment for nodal metastasis in melanoma, carries the risk of significant morbidity. Clinically apparent nodal tumor is likely to impact both preoperative lymphatic function and extent of soft tissue dissection required to clear the basin. We hypothesized that early dissection would be associated with less morbidity than delayed dissection at the time of clinical recurrence.
  
  
  METHODS
  The Multicenter Selective Lymphadenectomy Trial I randomized patients to wide excision of a primary melanoma with or without sentinel lymph node biopsy. Immediate completion lymph node dissection (early CLND) was performed when indicated in the SLN arm, while therapeutic dissection (delayed CLND) was performed at the time of clinical recurrence in the wide excision-alone arm. Acute and chronic morbidities were prospectively monitored.
  
  
  RESULTS
  Early CLND was performed in 225 patients, and in the wide excision-alone arm 132 have undergone delayed CLND. The 2 groups were similar for primary tumor features, body mass index, basin location, and demographics except age, which were higher for delayed CLND. The number of nodes evaluated and the number of positive nodes was greater for delayed CLND. There was no significant difference in acute morbidity, but lymphedema was significantly higher in the delayed CLND group (20.4% vs. 12.4%, P = .04). Length of inpatient hospitalization was also longer for delayed CLND.
  
  
  CONCLUSIONS
  Immediate nodal treatment provides critical prognostic information and a likely therapeutic effect for those patients with nodal involvement. These data show that early CLND is also less likely to result in lymphedema.
authors.affiliation: John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA. fariesm@jwci.org
authors.forename: Mark B
authors.initials: MB
authors.lastname: Faries
authors.forename: John F
authors.initials: JF
authors.lastname: Thompson
authors.forename: Alistair
authors.initials: A
authors.lastname: Cochran
authors.forename: Robert
authors.initials: R
authors.lastname: Elashoff
authors.forename: Edwin C
authors.initials: EC
authors.lastname: Glass
authors.forename: Nicola
authors.initials: N
authors.lastname: Mozzillo
authors.forename: Omgo E
authors.initials: OE
authors.lastname: Nieweg
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Roses
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Hoekstra
authors.forename: Constantine P
authors.initials: CP
authors.lastname: Karakousis
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Reintgen
authors.forename: Brendon J
authors.initials: BJ
authors.lastname: Coventry
authors.forename: He-Jing
authors.initials: HJ
authors.lastname: Wang
authors.forename: Donald L
authors.initials: DL
authors.lastname: Morton
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007902:Length of Stay; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000473:pathology* / Q000601:surgery; D008875:Middle Aged; D009017:Morbidity; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D055815:Young Adult